BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS

• US 20030092700A1
• Filed: 02/11/1999
• Published: 05/15/2003
• Est. Priority Date: 04/19/1996
• Status: Active Grant

• Current Assignee: Sanochemia Ltd. (Frantsits Family)
• Original Assignee: Sanochemia Ltd. (Frantsits Family)
• Inventors: JORDIS, ULRICH, CZOLLNER, LASZLO, FROHLICH, JOHANNES, KUENBURG, BERNHARD
• Granted Patent: US 6,638,925 B2
• Time in Patent Office: Days
• US Class Current: 514/217.01
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 471/08 Bridged systems
• CPC Class Codes: C07D 487/08 Bridged systems
• CPC Class Codes: C07D 491/10 Spiro-condensed systems
• CPC Class Codes: Y02P 20/55 Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

New derivatives of benzazepine, particularly of benzofuro[3a,3,2,ef][2]benzazepin of the general formula (I)

and new compounds of the general formula (III)

Drugs, containing compounds of formulas (I) and/or (III), which can be used successfully for the treatment of Alzheimer'"'"'s disease and related dementia conditions, as well as for the treatment of Langdon-Down syndrome, are also described.

Claims

1. Compounds of the general formula (I)

6. Drug, characterized in that it contains one, two or more compounds of claims 1 to 5 as active pharmaceutical ingredients.

7. The use of one, two or more of the acid addition salts of the compounds of the claims 1 to 5, their enantiomers and/or their pharmaceutically acceptable acid addition salts for the preparation of a drug for the treatment of Alzheimer'"'"'s disease and related dementia conditions.

8. The use of one, two or more of the acid addition salts of the compounds of the claims 1 to 5, their enantiomers and/or their pharmaceutically acceptable acid addition salts for the preparation of a drug for the treatment of trisomy 21 or related trisomy syndromes.

2. A compound of the general formula (II)

3. Compounds of the general formula (III) particularly to 2, 5-diazabicyclo[2.2.1]heptane:

4. A compound of claim 3 having the formula:

5. A compound of claim 3 having the formula: